Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-hIFNβ
- Development stage
- Phase 1
- Lead developer
- Siren Biotechnology
- Modality
- Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
AAV-hIFNβ (also known as SRN-101) is an experimental, clinical-stage adeno-associated virus (AAV)-vectored immuno-gene therapy developed by Siren Biotechnology for the treatment of high-grade gliomas, including glioblastoma (GBM). It consists of a recombinant AAV vector (typically AAV9) carrying the gene for human interferon-beta (hIFNβ). Delivered locally via MRI-guided convection-enhanced delivery (CED), the vector transduces tumor and surrounding brain cells to continuously produce and secrete hIFNβ, thereby overcoming the short half-life and systemic toxicities associated with recombinant IFNβ protein. Secreted hIFNβ signals through the type I interferon receptor (IFNAR) to induce tumor cell apoptosis, remodel the immunosuppressive tumor microenvironment, and stimulate a potent anti-tumor immune response. The FDA has granted SRN-101 Orphan Drug, Rare Pediatric Disease, and Fast Track designations for high-grade gliomas.
- Other names
- AAV-IFN-bAAV-IFN-βAAV-hIFNbAAV-hIFNβAAV9-hIFNbAAV-9-hIFNbAAV 9-hIFNbAAV9-hIFNβscAAV9-hIFNbscAAV-9-hIFNbscAAV 9-hIFNbscAAV9-hIFNβ
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IRF9 (Interferon regulatory factor 9)JAK1 (Janus kinase 1)STAT1 (Signal transducer and activator of transcription protein 1)STAT2TYK2 (Tyrosine kinase 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on AAV-hIFNβ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-hIFNβ.